Nurix Therapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nurix Therapeutics, Inc. (Nasdaq: NRIX) on November 10, 2025, reporting events that occurred on November 6, 2025. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. As a Form 8-K focused on corporate governance, it contains no financial performance data for the reporting period.
Material Changes
The primary material change reported is the appointment of Roger Dansey, M.D., to the Board of Directors and the Clinical and Commercialization Committee, effective November 6, 2025. Dr. Dansey serves as a Class III director with a term expiring at the 2026 annual meeting of stockholders.
Compensation and Equity Arrangements
- Cash Retainer: Dr. Dansey will receive a pro rata portion of the $50,000 annual director retainer and a pro rata portion of the $7,500 annual committee retainer for the remainder of the fiscal year ending November 30, 2025.
- Initial Equity Award: A stock option to purchase 50,000 shares of common stock was granted on November 6, 2025. The exercise price equals the closing sale price on the grant date. The award vests monthly over three years, contingent on continued service.
- Annual Equity Award: Dr. Dansey will receive customary annual equity compensation at each annual meeting, currently consisting of a stock option to purchase 25,000 shares, vesting on the earlier of the next annual meeting or one year from grant.
- Acceleration: Both the Initial Award and Annual Awards accelerate in full upon the consummation of a Corporate Transaction.
Risks and Contingencies
The filing states there are no family relationships between Dr. Dansey and existing directors or officers, and no direct or indirect material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K. The company has executed a standard indemnification agreement with Dr. Dansey.
Investor Verification Checklist
- Verify the closing stock price on November 6, 2025, to determine the exercise price of the 50,000 share option grant.
- Review the Company's 2020 Equity Incentive Plan to understand the specific definition of a "Corporate Transaction" triggering award acceleration.
- Confirm the exact vesting schedule start date and monthly vesting amounts for the Initial Award.
- Check subsequent filings for the formal press release (Exhibit 99.1) referenced in the document for additional context on Dr. Dansey's qualifications.